The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease characterized by worsening dyspnea and lung function and has a median survival of 2–3 years. Forced vital capacity (FVC) is the primary endpoint used most commonly in IPF clinical trials as it is the best...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Grace Hyun J., Goldin, Jonathan G., Hayes, Wendy, Oh, Andrea, Soule, Benjamin, Du, Shuyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013716/
https://www.ncbi.nlm.nih.gov/pubmed/33781141
http://dx.doi.org/10.1177/17534666211004238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013716/
https://www.ncbi.nlm.nih.gov/pubmed/33781141
http://dx.doi.org/10.1177/17534666211004238

Ejemplares similares